News

CEPI partners with Themis to advance vaccines against Lassa fever and MERS

Details

Today Themis and the Coalition for Epidemic Preparedness Innovations (CEPI) announced a partnership under which Themis will provide advanced vaccine development and manufacturing for Lassa fever and MERS. The investment of up to $37,500,000 represents an innovative approach to funding vaccine development, unlocking research and development potential so that vaccines are ready for efficacy studies during an outbreak. 

Themis establishes Scientific Advisory Board of experts in virology and vaccine development

Details

Themis has established a Scientific Advisory Board (SAB) with the appointment of Christian W. Mandl, Ph.D., MD, W. Paul Duprex, Ph.D., Stephen J. Thomas, MD and Nadia G. Tornieporth, MD. The newly-formed SAB brings a wealth of experience in molecular virology, viral pathogenesis and vaccine development. The purpose of the SAB will be to advise Themis as it continues to develop its pipeline of urgently needed vaccines and immune system activation approaches. 

Physicians at Helios gain access to Amboss platform

Details

Helios now provides its approx. 12,000 employed physicians with free access to the knowledge platform Amboss. This gives physicians the opportunity to receive answers to clinical questions on the basis of specific diagnostic and therapeutic recommendations at any time via their smartphone or computer. 

  1. Immatics appoints Thomas Ulmer as Chief Financial Officer
  2. Themis raises EUR 10 million in Series C financing to advance clinical pipeline
  3. Themis presents Phase II interim results for Chikungunya vaccine candidate at ASTMH 2017
  4. Ambu acquires Wellington Partners portfolio company invendo medical
© Wellington Partners, 2019.